Kite Pharma
Santa Monica
California
United States
301 articles with Kite Pharma
-
Yescarta is the first treatment in nearly 30 years to improve overall survival in relapsed/refractory large B-cell lymphoma R/R LBCL, according to Gilead's Kite Pharma.
-
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
3/21/2023
Kite, a Gilead Company (Nasdaq: GILD), today announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study.
-
Kite Completes Acquisition of Tmunity
2/22/2023
Kite, a Gilead Company (NASDAQ: GILD), today announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.
-
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
2/9/2023
Kite’s Tecartus ® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
-
Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma
12/22/2022
Kite Pharma, Inc., a Gilead Company, (hereafter, Kite) (NASDAQ: GILD) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) (TSE: 4568) today jointly announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has approved Yescarta (axicabtagene ciloleucel).
-
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer
12/20/2022
Kite today announced that the companies have signed an agreement in which Kite will acquire Tmunity, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.
-
Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months
12/12/2022
Kite today announced three-year follow-up data from the pivotal ZUMA-5 study for Yescarta® (axicabtagene ciloleucel) in relapsed or refractory (r/r) indolent non-Hodgkin lymphoma (iNHL), showing continued response in 52% of all enrolled patients, and prolonged duration of progression-free survival (PFS) in the Phase 2 study, presented at the 2022 American Society of Hematology (ASH) Annual Meeting & Exposition.
-
New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response
12/12/2022
Kite, a Gilead Company (Nasdaq: GILD), today announced findings from follow-up analyses of two pivotal studies (ZUMA-2 and ZUMA-3) of the CAR T-cell therapy Tecartus® (brexucabtagene autoleucel).
-
Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite’s Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma
12/11/2022
Kite, a Gilead Company, announced findings from two new analyses of the landmark ZUMA-7 trial of Yescarta®, the largest and longest follow-up of a CAR T-cell therapy versus standard of care in patients with relapsed or refractory large B-cell lymphoma.
-
Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis
12/11/2022
Kite, a Gilead Company, announced results from one of the largest real-world analyses of patients who received CAR T-cell therapy assessing the impact of time from leukapheresis to infusion for Yescarta® in adult patients with relapsed or refractory large B-cell lymphoma.
-
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
12/9/2022
Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma.
-
Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma
12/9/2022
Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx's lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma.
-
Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan
12/7/2022
Kite Pharma, Inc., a Gilead Company, (hereafter Kite) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) today jointly announced the revision of their 2017 partnership agreement, which gave Daiichi Sankyo exclusive rights to develop, manufacture and commercialize Yescarta (axicabtagene ciloleucel) in Japan.
-
Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022
11/3/2022
Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will support 30 data presentations, including seven oral presentations in large B-cell lymphoma (LBCL), and two oral presentations on investigator-sponsored studies in acute myeloid leukemia (AML) during the 64th Annual American Society of Hematology (ASH) Annual Meeting (December 10-13).
-
Kite Pharma entered into a global licensing deal with Refuge Biotechnologies to leverage the latter's propriety gene expression plaform and develop potential blood cancer therapies.
-
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers
10/20/2022
Kite, a Gilead Company (Nasdaq: GILD) and Refuge Biotechnologies, Inc. (“Refuge”), today announced that Kite has entered into an exclusive, worldwide license agreement with Refuge, a synthetic biology company for cancer immunotherapy, for exclusive rights to utilize Refuge’s proprietary gene expression platform to develop potential treatments for blood cancers.
-
Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
9/16/2022
Kite’s CAR T-cell Therapy Yescarta ® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma.
-
Tecartus® Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up of Two Pivotal Studies Including Longest Ever Follow-Up of a CAR T-cell Therapy in Mantle Cell Lymphoma
6/4/2022
Kite, a Gilead Company, announced longer-term follow-up results from two pivotal studies of the CAR T-cell therapy Tecartus®.
-
Nkarta announced that two of its therapies have shown complete remission in patients with blood cancer. These results are the latest development in the treatment of difficult-to-treat blood cancers.
-
Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland
4/19/2022
Kite’s Global CAR T-Cell Therapy Manufacturing Network Increasing Capacity by 50% to Meet Patient Demand for New Cancer Therapies.